Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.4057 +0.0017 (+0.42%)
Official Closing Price Updated: 4:10 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected
Discover how Anson Funds settled with the SEC for $2.25M over an undisclosed collaboration with short seller impacting cannabis stocks 
Via Benzinga
Topics Cannabis Regulatory Compliance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Publication of Key Study in European Journal
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
From IGC Pharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Initiates Patient Enrollment in Phase 2 Trial Investigating IGC-AD1
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
From IGC Pharma Inc.
Via Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Management Hosting Meetings at Upcoming BIO International Convention 2024
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma to Attend BIO International Convention 2024
From IGC Pharma Inc.
Via Business Wire
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings 
Via News Direct
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Cannabis
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news for Wednesday morning! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Cannabis
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo. 
Via Benzinga
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
From IGC Pharma, Inc.
Via Business Wire
Who's Who In Cannabis: Latest Executive Changes You Should Know About
 
Via Benzinga
BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Adds Advisor in Artificial Intelligence
From IGC Pharma, Inc.
Via Business Wire
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
--News Direct-- 
Via News Direct
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
 
Via Benzinga
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company
Via Investor Brand Network
Topics Artificial Intelligence
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
From IGC Pharma Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Interim Results from Phase 2 Study Evaluating Treatment to Reduce Alzheimer’s Agitation
Via Investor Brand Network
Topics Artificial Intelligence
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability... 
Via Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. 
Via Benzinga
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Benzinga Virtual Healthcare Summit 2024
Via Investor Brand Network
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.